Wall Street Zen cut shares of Cardiol Therapeutics (NASDAQ:CRDL – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.
Other equities analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Wednesday, September 23rd. Canaccord Genuity Group lifted their target price on shares of Cardiol Therapeutics from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, August 17th. B. Riley Financial started coverage on shares of Cardiol Therapeutics in a research report on Wednesday, August 26th. They issued a “buy” rating and a $11.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiol Therapeutics in a research note on Monday, September 21st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.
Check Out Our Latest Stock Analysis on CRDL
Cardiol Therapeutics Trading Down 2.0%
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Research analysts predict that Cardiol Therapeutics will post -0.19 EPS for the current year.
Hedge Funds Weigh In On Cardiol Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in CRDL. Royal Bank of Canada boosted its stake in shares of Cardiol Therapeutics by 62.3% in the first quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock worth $29,000 after acquiring an additional 8,306 shares during the last quarter. PVG Asset Management Corp increased its position in shares of Cardiol Therapeutics by 10.3% during the first quarter. PVG Asset Management Corp now owns 107,165 shares of the company’s stock worth $145,000 after purchasing an additional 10,000 shares in the last quarter. Parallel Advisors LLC acquired a new position in Cardiol Therapeutics in the 3rd quarter valued at $32,000. Concurrent Investment Advisors LLC acquired a new position in Cardiol Therapeutics in the 2nd quarter valued at $27,000. Finally, Cibc World Market Inc. acquired a new position in Cardiol Therapeutics in the 3rd quarter valued at $55,000. Hedge funds and other institutional investors own 12.49% of the company’s stock.
About Cardiol Therapeutics
Cardiol Therapeutics is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart. The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure.
Further Reading
- Five stocks we like better than Cardiol Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
